Head-to-head · WeighScore
HealthOn vs Hims & Hers
By GLP-1 ScorecardUpdated
Score comparison
Hims & Hers has the higher recorded score — 75.6/100 to 54.5/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | HealthOn | Hims & Hers |
|---|---|---|
| WeighScore | 54.5/100 | 75.6/100 |
| Grade | C | C |
| Site position | #504 | #56 |
| Semaglutide | $189/mo (starting dose, 12-month plan, compounded) | $199/mo |
| Tirzepatide | $290/mo (starting dose, 12-month plan, compounded) | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #504 · C
FDAWarning letter issued to Healthon Inc. dba Healthon in September 2025. See the FDA warning-letter database.
Strengths
- Both compounded semaglutide and tirzepatide available
- Weight-loss pricing starts at $189/mo for compounded semaglutide
What to consider
- No visible LegitScript certification or PCAB accreditation
- State availability not publicly disclosed
- Lowest advertised prices require a 12-month plan commitment
- FDA issued Healthon Inc. dba Healthon a warning letter in September 2025; the letter is public in FDA's warning-letter database
Site position #56 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
What to consider
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.